IMLYGIC (talimogene laherparepvec)

OFFICE ADMINISTRATION - INTRALESIONAL INJECTION 

Indications for Prior Authorization:

Melanoma, unresectable

  • Treatment (local) of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery
  • Limitations of use: Has not been shown to improve overall survival or have an effect on visceral metastases

All of the following must be met as a condition for coverage:

  • Treatment (local) of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery
  • Patient has not responded to, tried/failed, or is unable to take Yervoy

This Medication is Not Approvable for the following condition(s):

  • Any condition not listed above as an approved indication

Dosing:

Maximum dose

  • The total injection volume for each treatment visit (for all injected lesions combined) is 4 mL according to the prescribing information

Approval: 

One year


 

Last review date: July 25, 2016

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone